Skip to main content
SpringerLink
Log in
Book cover

Molecularly Targeted Therapy for Childhood Cancer pp 155–176Cite as

Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes

  • Chapter
  • First Online:

  • 601 Accesses

Abstract

New technologies have improved our understanding of hematopoietic and leukemia biology, and expanding knowledge of underlying molecular pathways and genomic aberrations is facilitating the development of new therapies for relapsed and refractory disease (Bhojwani et al. 2006; Carroll et al. 2006). Myelodysplasia and associated syndromes constitute a broad range of bone marrow dysfunction, characterized by variable clinical features; cytopenias due to bone marrow production and/or dysfunction and insufficiencies are typical. Clinical symptoms are frequently due to anemia, neutropenia, and/or thrombocytopenia, and transfusion dependence is common although not universal. The progression from myelodysplastic syndromes (MDS) to leukemia, particularly in children, is unequivocal, although the time course over which this occurs is highly variable. Risk factors for progression and lability of disease have been identified, and great effort is being made to identify the molecular triggers in MDS that are both causative and clinically relevant.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Bhojwani D, Kang H, Moskowitz NP, et al. Biologic pathways associated with relapse in childhood acute lymphoblastic leukemia: a Children’s Oncology Group study. Blood 2006:108(2):711–717.

    Article  PubMed  CAS  Google Scholar 

  • Carroll WL, Bhojwani D, Min DJ, et al. Childhood acute lymphoblastic leukemia in the age of genomics. Pediatr Blood Cancer 2006:46(5):570–578.

    Article  PubMed  Google Scholar 

  • Rollison DE, Howlader N, Smith MT, et al. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001–2004, using data from the NAACCR and SEER programs. Blood 2008:112(1):45–52.

    Article  PubMed  CAS  Google Scholar 

  • Finn R. Medicare analysis suggests MDS is “severely underestimated.” Oncol Rep 2009(Spring): 21(1):37–38.

    Google Scholar 

  • Ma X, Does M, Raza A, et al. Myelodysplastic syndromes: incidence and survival in the United States. Cancer 2007:109(8):1536–1542.

    Article  PubMed  Google Scholar 

  • Locatelli F, Zecca M, Pession A, et al. Myelodysplastic syndromes: the pediatric point of view. Haematologica 1995:80(3):268–279.

    PubMed  CAS  Google Scholar 

  • Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009:113(13):2895–2901.

    Article  PubMed  CAS  Google Scholar 

  • Bennett JM, Catovsky D, Daniel MT, et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982:51(2):189–199.

    PubMed  CAS  Google Scholar 

  • Jaffe ES, Harris NL, Stein H, et al. Tumours of the haematolpoietic and lyphoid tissues. In: Tumours WHOCo, editor. Pathology and Genetics of Tumours of the Haematopoietic and Lymphoid Tissues. Lyon: International Agency for Research on Cancer; 2001

    Google Scholar 

  • Greenberg P, Cox C, LeBeau MM, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997:89(6):2079–2088.

    PubMed  CAS  Google Scholar 

  • Kaushansky. Erratum. Blood 1998:91(3):1100.

    Google Scholar 

  • Hasle H, Niemeyer CM, Chessells JM, et al. A pediatric approach to the WHO classification of myelodysplastic and myeloproliferative diseases. Leukemia 2003:17(2):277–282.

    Article  PubMed  CAS  Google Scholar 

  • Mandel K, Dror Y, Poon A, et al. A practical, comprehensive classification for pediatric myelodysplastic syndromes: the CCC system. J Pediatr Hematol Oncol 2002:24(7):596–605.

    Article  PubMed  Google Scholar 

  • Lorand-Metze I, Pinheiro MP, Ribeiro E, et al. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications. Leuk Res 2004:28(6):587–594.

    Article  PubMed  Google Scholar 

  • Occhipinti E, Correa H, Yu L, et al. Comparison of two new classifications for pediatric myelodysplastic and myeloproliferative disorders. Pediatr Blood Cancer 2005:44(3):240–244.

    Article  PubMed  Google Scholar 

  • Alter BP. Fanconi’s anemia and malignancies. Am J Hematol 1996:53(2):99–110.

    Article  PubMed  CAS  Google Scholar 

  • Alter BP. Bone marrow failure syndromes in children. Pediatr Clin North Am 2002:49(5): 973–988.

    Article  PubMed  Google Scholar 

  • Homans AC, Verissimo AM, Vlacha V. Transient abnormal myelopoiesis of infancy associated with trisomy 21. Am J Pediatr Hematol Oncol 1993:15(4):392–399.

    PubMed  CAS  Google Scholar 

  • Creutzig U, Ritter J, Vormoor J, et al. Myelodysplasia and acute myelogenous leukemia in Down’s syndrome. A report of 40 children of the AML-BFM Study Group. Leukemia 1996:10(11): 1677–1686.

    CAS  Google Scholar 

  • Rischewski JR, Clausen H, Leber V, et al. A heterozygous frameshift mutation in the Fanconi anemia C gene in familial T-ALL and secondary malignancy. Klin Padiatr 2000:212(4):174–176.

    Article  PubMed  CAS  Google Scholar 

  • Surico G, Muggeo P, Rigillo N, et al. Concurrent Langerhans cell histiocytosis and myelodysplasia in children. Med Pediatr Oncol 2000:35(4):421–425.

    Article  PubMed  CAS  Google Scholar 

  • Cetin M, Hicsonmez G, Gogus S. Myelodysplastic syndrome associated with Griscelli syndrome. Leuk Res 1998:22(9):859–862.

    Article  PubMed  CAS  Google Scholar 

  • Ohara A, Kojima S, Hamajima N, et al. Myelodysplastic syndrome and acute myelogenous leukemia as a late clonal complication in children with acquired aplastic anemia. Blood 1997:90(3):1009–1013.

    PubMed  CAS  Google Scholar 

  • Winick NJ, McKenna RW, Shuster JJ, et al. Secondary acute myeloid leukemia in children with acute lymphoblastic leukemia treated with etoposide. J Clin Oncol 1993:11:209–217.

    PubMed  CAS  Google Scholar 

  • Pui CH, Ribeiro RC, Hancock ML, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991:325(24):1682–1687.

    Article  PubMed  CAS  Google Scholar 

  • Tew KD, Colvin OM, Chabner BA. Alkylating agents. In: Chabner BA, Longo DL, editors. Cancer Chemotherapy and Biotherapy. Third ed. Phliadelphia: Lippincott Williams & Wilkins; 2001, pp 397–398.

    Google Scholar 

  • Smith MA, McCaffrey RP, Karp JE. The secondary leukemias: challenges and research directions. J Natl Cancer Inst 1996:88:407–418.

    Article  PubMed  CAS  Google Scholar 

  • Bo J, Schroder H, Kristinsson J, et al. Possible carcinogenic effect of 6-mercaptopurine on bone marrow stem cells: relation to thiopurine metabolism. Cancer 1999:86(6):1080–1086.

    Article  PubMed  CAS  Google Scholar 

  • Felix CA, Hosler MR, Winick NJ, et al. ALL-1 gene rearrangements in DNA topoisomerase II inhibitor-related leukemia in children. Blood 1995:85(11):3250–3256.

    PubMed  CAS  Google Scholar 

  • Privitera E, Wang W, Raimondi SC. Monosomy 7 and unbalanced t(1;7) in an adolescent boy with myelodysplastic syndrome. Leukemia 1992:6(7):742–745.

    PubMed  CAS  Google Scholar 

  • Yesilipek MA, Luleci G, Velipasaoglu S, et al. Monosomy 7 myelodysplasia in childhood. Two case reports. Acta Haematol 1994:92(1):36–38.

    Article  PubMed  CAS  Google Scholar 

  • Maris JM, Wiersma SR, Mahgoub N, et al. Monosomy 7 myelodysplastic syndrome and other second malignant neoplasms in children with neurofibromatosis type 1. Cancer 1997:79(7): 1438–1446.

    Article  PubMed  CAS  Google Scholar 

  • Harrison KJ, Massing B, McKenna C, et al. Molecular cytogenetic analysis of monosomy 7 in pediatric patients with myelodysplastic syndrome. Am J Hematol 1995:48(2):88–91.

    Article  PubMed  CAS  Google Scholar 

  • Chantrain C, Vermylen C, Michaux L, et al. Clonal monosomy 7 and 5q – in a child with myelodysplastic syndrome. Pediatr Hematol Oncol 2000:17(6):505–509.

    Article  PubMed  CAS  Google Scholar 

  • Chakraborty S, Sun CL, Francisco L, et al. Accelerated telomere shortening precedes development of therapy-related myelodysplasia or acute myelogenous leukemia after autologous transplantation for lymphoma. J Clin Oncol 2009:27(5):791–798.

    Article  PubMed  Google Scholar 

  • Taketani T, Taki T, Takita J, et al. AML1/RUNX1 mutations are infrequent, but related to AML-M0, acquired trisomy 21, and leukemic transformation in pediatric hematologic malignancies. Genes Chromosomes Cancer 2003:38(1):1–7.

    Article  PubMed  CAS  Google Scholar 

  • Tartaglia M, Niemeyer CM, Fragale A, et al. Somatic mutations in PTPN11 in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003:34(2):148–150.

    Article  PubMed  CAS  Google Scholar 

  • Lo Coco F, Pisegna S, Diverio D. The AML1 gene: a transcription factor involved in the pathogenesis of myeloid and lymphoid leukemias. Haematologica 1997:82(3):364–370.

    PubMed  CAS  Google Scholar 

  • Perkins D, Brennan S, Carstairs K, et al. Regional cancer cytogenetics: a report on 1,143 diagnostic cases. Cancer Genet Cytogenet 1997:96(1):64–80.

    Article  PubMed  CAS  Google Scholar 

  • Block AW, Carroll AJ, Hagemeijer A, et al. Rare recurring balanced chromosome abnormalities in therapy-related myelodysplastic syndromes and acute leukemia: report from an international workshop. Genes Chromosomes Cancer 2002:33(4):401–412.

    Article  PubMed  Google Scholar 

  • Woods WG, Neudorf S, Gold S, et al. A comparison of allogeneic bone marrow transplantation, autologous bone marrow transplantation, and aggressive chemotherapy in children with acute myeloid leukemia in remission. Blood 2001:97(1):56–62.

    Article  PubMed  CAS  Google Scholar 

  • Huang ME, Yu-chen Y, Shu-rong C, et al. Use of all-trans retinoic acid in the treatment of acute promyelocytic leukemia. Blood 1988:72:567–572.

    PubMed  CAS  Google Scholar 

  • Singal R, Ginder GD. DNA methylation. Blood 1999:93(12):4059–4070.

    PubMed  CAS  Google Scholar 

  • Esteller M, Corn PG, Baylin SB, et al. A gene hypermethylation profile of human cancer. Cancer Res 2001:61(8):3225–3229.

    PubMed  CAS  Google Scholar 

  • Das PM, Singal R. DNA methylation and cancer. J Clin Oncol 2004:22(22):4632–4642.

    Article  PubMed  CAS  Google Scholar 

  • Vidal DO, Paixao VA, Brait M, et al. Aberrant methylation in pediatric myelodysplastic syndrome. Leuk Res 2007:31(2):175–181.

    Article  PubMed  CAS  Google Scholar 

  • Cameron EE, Bachman KE, Myohanen S, et al. Synergy of demethylation and histone deacetylase inhibition in the re-expression of genes silenced in cancer. Nat Genet 1999:21: 103–107.

    Article  PubMed  CAS  Google Scholar 

  • Rountree MR, Bachman KE, Herman JG, et al. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001:20(24):3156–3165.

    Article  PubMed  CAS  Google Scholar 

  • Rountree MR, Bachman KE, Baylin SB. DNMT1 binds HDAC2 and a new co-repressor, DMAP1, to form a complex at replication foci. Nat Genet 2000:25(3):269–277.

    Article  PubMed  CAS  Google Scholar 

  • Jones PL, Wolffe AP. Relationships between chromatin organization and DNA methylation in determining gene expression. Semin Cancer Biol 1999:9(5):339–347.

    Article  PubMed  CAS  Google Scholar 

  • Zhou L, Opalinska JB, Sohal DP, et al. Integrative genomic analysis reveals aberrant epigenetic marks in MDS that can be seen in peripheral blood leucocytes. In: Dunbar CE, editor; 2008; San Francisco, CO. American Society of Hematology. p 223.

    Google Scholar 

  • Kuerbitz SJ, Pahys J, Wilson A, et al. Hypermethylation of the imprinted NNAT locus occurs frequently in pediatric acute leukemia. Carcinogenesis 2002:23(4):559–564.

    Article  PubMed  CAS  Google Scholar 

  • Imamura T, Kakazu N, Hibi S, et al. Rearrangement of the MOZ gene in pediatric therapy-related myelodysplastic syndrome with a novel chromosomal translocation t(2;8)(p23;p11). Genes Chromosomes Cancer 2003:36(4):413–419.

    Article  PubMed  CAS  Google Scholar 

  • Uchida T, Kinoshita T, Nagai H, et al. Hypermethylation of the p15INK4B gene in myelodysplastic syndromes. Blood 1997:90(4):1403–1409.

    PubMed  CAS  Google Scholar 

  • Jones PA, Laird PW. Cancer epigenetics comes of age. Nat Genet 1999:21(2):163–167.

    Article  PubMed  CAS  Google Scholar 

  • Jiang Y, Dunbar A, Gondek LP, et al. Aberrant DNA methylation is a dominant mechanism in MDS progression to AML. Blood 2009:113(6):1315–1325.

    Article  PubMed  CAS  Google Scholar 

  • Garcia-Manero G, Kantarjian HM, Sanchez-Gonzalez B, et al. Phase 1/2 study of the combination of 5-aza-2′-deoxycytidine with valproic acid in patients with leukemia. Blood 2006:108(10): 3271–3279.

    Article  PubMed  CAS  Google Scholar 

  • Scott SA, Lakshimikuttysamma A, Sheridan DP, et al. Zebularine inhibits human acute myeloid leukemia cell growth in vitro in association with p15INK4B demethylation and reexpression. Exp Hematol 2007:35(2):263–273.

    Article  PubMed  CAS  Google Scholar 

  • Shaker S, Bernstein M, Momparler LF, et al. Preclinical evaluation of antineoplastic activity of inhibitors of DNA methylation (5-aza-2′-deoxycytidine) and histone deacetylation (trichostatin A, depsipeptide) in combination against myeloid leukemic cells. Leuk Res 2003:27(5): 437–444.

    Article  PubMed  CAS  Google Scholar 

  • Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006:24(24):3895–3903.

    Article  PubMed  CAS  Google Scholar 

  • Flotho C, Claus R, Batz C, et al. The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells. Leukemia 2009:23:1019–1028.

    Article  PubMed  CAS  Google Scholar 

  • Kuendgen A, Schmid M, Schlenk R, et al. The histone deacetylase (HDAC) inhibitor valproic acid as monotherapy or in combination with all-trans retinoic acid in patients with acute myeloid leukemia. Cancer 2006:106(1):112–119.

    Article  PubMed  CAS  Google Scholar 

  • Kuendgen A, Knipp S, Fox F, et al. Results of a phase 2 study of valproic acid alone or in combination with all-trans retinoic acid in 75 patients with myelodysplastic syndrome and relapsed or refractory acute myeloid leukemia. Ann Hematol 2005:84 Suppl 1:61–66.

    Article  PubMed  CAS  Google Scholar 

  • Rosato RR, Almenara JA, Grant S. The histone deacetylase inhibitor MS-275 promotes differentiation or apoptosis in human leukemia cells through a process regulated by generation of reactive oxygen species and induction of p21CIP1/WAF1 1. Cancer Res 2003:63(13): 3637–3645.

    PubMed  CAS  Google Scholar 

  • Fouladi M, Furman WL, Chin T, et al. Phase I study of depsipeptide in pediatric patients with refractory solid tumors: a Children’s Oncology Group report. J Clin Oncol 2006:24(22): 3678–3685.

    Article  PubMed  CAS  Google Scholar 

  • Murgo AJ. Clinical trials of arsenic trioxide in hematologic and solid tumors: overview of the National Cancer Institute Cooperative Research and Development Studies. Oncologist 2001:6 Suppl 2:22–28.

    Article  PubMed  CAS  Google Scholar 

  • Sekeres MA, List A. Lenalidomide (Revlimid, CC-5013) in myelodysplastic syndromes: is it any good? Curr Hematol Rep 2005:4(3):182–185.

    PubMed  CAS  Google Scholar 

  • Sekeres MA, List A. Immunomodulation in myelodysplastic syndromes. Best Pract Res Clin Haematol 2006:19(4):757–767.

    Article  PubMed  CAS  Google Scholar 

  • Sekeres MA, Maciejewski JP, Giagounidis AA, et al. Relationship of treatment-related cytopenias and response to lenalidomide in patients with lower-risk myelodysplastic syndromes. J Clin Oncol 2008:26(36):5943–5949.

    Article  PubMed  Google Scholar 

  • Chang DH, Liu N, Klimek V, et al. Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications. Blood 2006:108(2):618–621.

    Article  PubMed  CAS  Google Scholar 

  • List A, Dewald G, Bennett J, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006:355(14):1456–1465.

    Article  PubMed  CAS  Google Scholar 

  • Raza A, Reeves JA, Feldman EJ, et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk, and intermediate-1 risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008:111(1):86–93.

    Article  PubMed  CAS  Google Scholar 

  • Gilheeney SW, Lyden DC, Sgouros S, et al. A phase II trial of thalidomide and cyclophosphamide in patients with recurrent or refractory pediatric malignancies. Pediatr Blood Cancer 2007:49(3): 261–265.

    Article  PubMed  Google Scholar 

  • Kieran MW, Turner CD, Rubin JB, et al. A feasibility trial of antiangiogenic (metronomic) chemotherapy in pediatric patients with recurrent or progressive cancer. J Pediatr Hematol Oncol 2005:27(11):573–581.

    Article  PubMed  Google Scholar 

  • Lopez-Aguilar E, Sepulveda-Vildosola AC, Betanzos-Cabrera Y, et al. Phase II study of metronomic chemotherapy with thalidomide, carboplatin-vincristine-fluvastatin in the treatment of brain stem tumors in children. Arch Med Res 2008:39(7):655–662.

    Article  PubMed  CAS  Google Scholar 

  • Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia 2003: 17(7):1301–1312.

    Article  PubMed  CAS  Google Scholar 

  • Boehrer S, Ades L, Braun T, et al. Erlotinib exhibits antineoplastic off-target effects in AML and MDS: a preclinical study. Blood 2008:111(4):2170–2180.

    Article  PubMed  CAS  Google Scholar 

  • Galili N, Cerny J, Raza A. Current treatment options: impact of cytogenetics on the course of myelodysplasia. Curr Treat Options Oncol 2007:8(2):117–128.

    Article  PubMed  Google Scholar 

  • Soriano AO, Yang H, Faderl S, et al. Safety and clinical activity of the combination of 5-azacytidine, valproic acid, and all-trans retinoic acid in acute myeloid leukemia and myelodysplastic syndrome. Blood 2007:110(7):2302–2308.

    Article  PubMed  CAS  Google Scholar 

  • Fouladi M, Park JR, Sun J, et al. A phase I trial and pharmacokinetic (PK) study of vorinostat (SAHA) in combination with 13 cis-retinoic acid (13cRA) in children with refractory neuroblastomas, medulloblastomas, primitive neuroectodermal tumors (PNETs), and atypical teratoid rhabdoid tumors. In: Grunberg SM, editor; 2008; Chicago, IL. American Society of Clinical Oncology. p 542s.

    Google Scholar 

  • Yao Q, Weigel B, Kersey J. Synergism between etoposide and 17-AAG in leukemia cells: critical roles for Hsp90, FLT3, topoisomerase II, Chk1, and Rad51. Clin Cancer Res 2007:13(5): 1591–1600.

    Article  PubMed  CAS  Google Scholar 

  • Weigel BJ, Blaney SM, Reid JM, et al. A phase I study of 17-allylaminogeldanamycin in relapsed/refractory pediatric patients with solid tumors: a Children’s Oncology Group study. Clin Cancer Res 2007:13(6):1789–1793.

    Article  PubMed  CAS  Google Scholar 

  • Bagatell R, Gore L, Egorin MJ, et al. Phase I pharmacokinetic and pharmacodynamic study of 17-N-allylamino-17-demethoxygeldanamycin in pediatric patients with recurrent or refractory solid tumors: a pediatric oncology experimental therapeutics investigators consortium study. Clin Cancer Res 2007:13(6):1783–1788.

    Article  PubMed  CAS  Google Scholar 

  • Stary J, Locatelli F, Niemeyer CM. Stem cell transplantation for aplastic anemia and myelodysplastic syndrome. Bone Marrow Transplant 2005:35 Suppl 1:S13–S16.

    Article  PubMed  Google Scholar 

  • Woodard P, Barfield R, Hale G, et al. Outcome of hematopoietic stem cell transplantation for pediatric patients with therapy-related acute myeloid leukemia or myelodysplastic syndrome. Pediatr Blood Cancer 2006:47(7):931–935.

    Article  PubMed  Google Scholar 

  • Kindwall-Keller T, Isola LM. The evolution of hematopoietic SCT in myelodysplastic syndrome. Bone Marrow Transplant 2009:43:597–609.

    Article  PubMed  CAS  Google Scholar 

  • Platzbecker U, Mohr B, von Bonin M, et al. Lenalidomide as induction therapy before allogeneic stem cell transplantation in a patient with proliferative CMML-2 and del(5q) not involving the EGR1 locus. Leukemia 2007:21(11):2384–2385.

    Article  PubMed  CAS  Google Scholar 

  • Kroger N. Epigenetic modulation and other options to improve outcome of stem cell transplantation in MDS. San Francisco, CA: American Society of Hematology; 2008.

    Google Scholar 

  • Reddy P, Maeda Y, Hotary K, et al. Histone deacetylase inhibitor suberoylanilide hydroxamic acid reduces acute graft-versus-host disease and preserves graft-versus-leukemia effect. Proc Natl Acad Sci USA 2004:101(11):3921–3926.

    Article  PubMed  CAS  Google Scholar 

  • Czibere A, Graef T, Lind J, et al. 5-Azacitidine in combination with donor lymphocyte infusion for treatment of patients with MDS or AML relapsing after allogeneic stem cell transplantation. Blood 2006:108:5341.

    Google Scholar 

  • Morerio C, Rapella A, Tassano E, et al. Gain of 1q in pediatric myelodysplastic syndromes. Leuk Res 2006:30(11):1437–1441.

    Article  PubMed  CAS  Google Scholar 

  • Mogul MJ, Brady K, Brothman AR, et al. Myelodysplastic syndrome presenting with clonal rearrangement isolated to chromosomal region 1q. Cancer Genet Cytogenet 1997:95(2): 210–212.

    Article  PubMed  CAS  Google Scholar 

  • Lahortiga I, Agirre X, Belloni E, et al. Molecular characterization of a t(1;3)(p36;q21) in a patient with MDS. MEL1 is widely expressed in normal tissues, including bone marrow, and it is not overexpressed in the t(1;3) cells. Oncogene 2004:23(1):311–316.

    Article  PubMed  CAS  Google Scholar 

  • Horsman DE, Massing BG, Chan KW, et al. Unbalanced translocation (1;7) in childhood myelodysplasia. Am J Hematol 1988:27(3):174–178.

    Article  PubMed  CAS  Google Scholar 

  • Stark B, Jeison M, Shohat M, et al. Involvement of 11p15 and 3q21q26 in therapy-related myeloid leukemia (t-ML) in children. Case reports and review of the literature. Cancer Genet Cytogenet 1994:75(1):11–22.

    Article  PubMed  CAS  Google Scholar 

  • Rubin CM, Larson RA, Anastasi J, et al. t(3;21)(q26;q22): a recurring chromosomal abnormality in therapy-related myelodysplastic syndrome and acute myeloid leukemia. Blood 1990:76(12): 2594–2598.

    PubMed  CAS  Google Scholar 

  • Dalla Torre CA, de Martino Lee ML, Yoshimoto M, et al. Myelodysplastic syndrome in childhood: report of two cases with deletion of chromosome 4 and the Philadelphia chromosome. Leuk Res 2002:26(6):533–538

    Article  PubMed  Google Scholar 

  • Pellier I, Le Moine PJ, Rialland X, et al. Myelodysplastic syndrome with t(5;12)(q31;p12-p13) and eosinophilia: a pediatric case with review of literature. J Pediatr Hematol Oncol 1996:18(3): 285–288.

    Article  PubMed  CAS  Google Scholar 

  • Wong WY, Wu SQ. Pentasomy 8 in pediatric myelodysplastic syndrome. Cancer Genet Cytogenet 2000:121(2):220–222.

    Article  PubMed  CAS  Google Scholar 

  • Taki T, Sako M, Tsuchida M, et al. The t(11;16)(q23;p13) translocation in myelodysplastic syndrome fuses the MLL gene to the CBP gene. Blood 1997:89(11):3945–3950.

    PubMed  CAS  Google Scholar 

  • Tosi S, Giudici G, Mosna G, et al. Identification of new partner chromosomes involved in fusions with the ETV6 (TEL) gene in hematologic malignancies. Genes Chromosomes Cancer 1998:21(3): 223–229.

    Article  PubMed  CAS  Google Scholar 

  • Coignet LJ, Lima CS, Min T, et al. Myeloid- and lymphoid-specific breakpoint cluster regions in chromosome band 13q14 in acute leukemia. Genes Chromosomes Cancer 1999:25(3): 222–229.

    Article  PubMed  CAS  Google Scholar 

  • Jamal R, Taketani T, Taki T, et al. Coduplication of the MLL and FLT3 genes in patients with acute myeloid leukemia. Genes Chromosomes Cancer 2001:31(2):187–190.

    Article  PubMed  CAS  Google Scholar 

  • Hellstrom-Lindberg E, Cazzola M. The role of JAK2 mutations in RARS and other MDS. Hematology Am Soc Hematol Educ Program 2008:2008:52–59.

    Article  Google Scholar 

  • Side LE, Emanuel PD, Taylor B, et al. Mutations of the NF1 gene in children with juvenile myelomonocytic leukemia without clinical evidence of neurofibromatosis, type 1. Blood 1998:92(1): 267–272.

    PubMed  CAS  Google Scholar 

  • Zhang Y, Zhang M, Yang L, et al. NPM1 mutations in myelodysplastic syndromes and acute myeloid leukemia with normal karyotype. Leuk Res 2007:31(1):109–111.

    Article  PubMed  CAS  Google Scholar 

  • Silveira CG, Oliveira FM, Valera ET, et al. New recurrent deletions in the PPARgamma and TP53 genes are associated with childhood myelodysplastic syndrome. Leuk Res 2009:33(1):19–27.

    Article  PubMed  CAS  Google Scholar 

  • Mahgoub N, Parker RI, Hosler MR, et al. RAS mutations in pediatric leukemias with MLL gene rearrangements. Genes Chromosomes Cancer 1998:21(3):270–275.

    Article  PubMed  CAS  Google Scholar 

  • Gafanovich A, Ramu N, Krichevsky S, et al. Microsatellite instability and p53 mutations in pediatric secondary malignant neoplasms. Cancer 1999:85(2):504–510.

    Article  PubMed  CAS  Google Scholar 

  • Kratz CP, Niemeyer CM, Castleberry RP, et al. The mutational spectrum of PTPN11 in juvenile myelomonocytic leukemia and Noonan syndrome/myeloproliferative disease. Blood 2005:106(6):2183–2185.

    Article  PubMed  CAS  Google Scholar 

  • Bentires-Alj M, Paez JG, David FS, et al. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia. Cancer Res 2004:64(24):8816–8820.

    Article  PubMed  CAS  Google Scholar 

  • Loh ML, Vattikuti S, Schubbert S, et al. Mutations in PTPN11 implicate the SHP-2 phosphatase in leukemogenesis. Blood 2004:103(6):2325–2331.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. The University of Colorado Cancer Center and The Center for Cancer and Blood Disorders, The Children’s Hospital, University of Colorado Denver, Pediatrics Mail Stop 8302, 6511, Aurora, CO, 80045, USA

    Lia Gore

Authors
  1. Lia Gore
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Lia Gore .

Editor information

Editors and Affiliations

  1. Director, Center for Childhood Cancer, Nationwide Children’s Hospital, The Research Institute, 700 Children’s Drive 332, Columbus, 43205, Ohio, USA

    Peter J. Houghton

  2. Johns Hopkins The Bunting & Blaustein Ca, Medicine Kimmel Comprehensive Cancer Cen, Orleans Street 1650, Baltimore, 21231, Maryland, USA

    Robert J. Arceci

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Gore, L. (2010). Molecularly Targeted Therapies in Pediatric Myelodysplastic Syndromes. In: Houghton, P., Arceci, R. (eds) Molecularly Targeted Therapy for Childhood Cancer. Springer, New York, NY. https://doi.org/10.1007/978-0-387-69062-9_9

Download citation

Publish with us

Policies and ethics

Search

Navigation